ASTRAZENECA PHARMA INDIA Financial Statement Analysis
|
||
|
The Revenues of ASTRAZENECA PHARMA INDIA have increased by 32.59% YoY .
The Earnings Per Share (EPS) of ASTRAZENECA PHARMA INDIA has increased by 62.01 % YoY. |
||
ASTRAZENECA PHARMA INDIA Last 5 Annual Financial Results
[BOM: 506820|NSE : ASTRAZEN]
| Standalone | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹2,276 Cr | ₹1,716 Cr | ₹1,296 Cr | ₹1,003 Cr | ₹806 Cr |
| Expenses | ₹2,014 Cr | ₹1,462 Cr | ₹1,111 Cr | ₹838 Cr | ₹719 Cr |
| Operating Profit (Excl OI) | ₹262 Cr | ₹254 Cr | ₹184 Cr | ₹165 Cr | ₹86 Cr |
| Other Income | ₹28 Cr | ₹41 Cr | ₹35 Cr | ₹26 Cr | ₹15 Cr |
| Interest | ₹4.49 Cr | ₹1.46 Cr | ₹1.20 Cr | ₹0.63 Cr | ₹0.95 Cr |
| Depreciation | ₹29 Cr | ₹40 Cr | ₹15 Cr | ₹16 Cr | ₹17 Cr |
| Profit Before Tax | ₹252 Cr | ₹156 Cr | ₹220 Cr | ₹134 Cr | ₹83 Cr |
| Profit After Tax | ₹188 Cr | ₹116 Cr | ₹162 Cr | ₹99 Cr | ₹62 Cr |
| Earnings Per Share (Rs) | ₹75.01 | ₹46.30 | ₹64.60 | ₹39.72 | ₹24.64 |
| PAT Margin (%) | 8.22 | 6.72 | 12.40 | 9.85 | 7.61 |
| ROE(%) | 23.02 | 15.73 | 24.95 | 18.13 | 12.78 |
| ROCE(%) | 31.24 | 21.29 | 33.94 | 24.49 | 17.36 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 20,225.1 Cr |
| Revenue (TTM) | : | ₹ 2,275.6 Cr |
| Net Profit(TTM) | : | ₹ 187.5 Cr |
| EPS (TTM) | : | ₹ 75.0 |
| P/E (TTM) | : | 107.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ASTRAZENECA PHARMA INDIA | 3.9% | -0.5% | -10.4% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.8% | 6.8% | 17.8% |
| DIVIS LABORATORIES | 6.7% | 18.5% | 12.2% |
| TORRENT PHARMACEUTICALS | -3.7% | 5.5% | 39.8% |
| CIPLA | 5.7% | 0.6% | -1.4% |
| DR REDDYS LABORATORIES | -2% | -15.8% | -8.4% |
| MANKIND PHARMA | 1.4% | 1.8% | -2% |
| LUPIN | 2.3% | 1.2% | 25.9% |
| ZYDUS LIFESCIENCES | 0.8% | 0.9% | 15% |
ASTRAZENECA PHARMA INDIA Revenues
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | 32.59 % |
| 5 Yr CAGR | 29.64 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,276 Cr | 32.59 | |
| Mar2025 | ₹1,716 Cr | 32.48 | |
| Mar2024 | ₹1,296 Cr | 29.17 | |
| Mar2023 | ₹1,003 Cr | 24.50 | |
| Mar2022 | ₹806 Cr | - | |
ASTRAZENECA PHARMA INDIA Operating Profit
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | 3.17 % |
| 5 Yr CAGR | 32.05 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹262 Cr | 3.17 | |
| Mar2025 | ₹254 Cr | 37.69 | |
| Mar2024 | ₹184 Cr | 11.71 | |
| Mar2023 | ₹165 Cr | 91.60 | |
| Mar2022 | ₹86 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -22.23 % |
| 5 Yr CAGR | 1.84 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 11.51% | -22.23 | |
| Mar2025 | 14.8% | 3.93 | |
| Mar2024 | 14.24% | -13.49 | |
| Mar2023 | 16.46% | 53.83 | |
| Mar2022 | 10.7% | - | |
ASTRAZENECA PHARMA INDIA Profit After Tax
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | 62.02 % |
| 5 Yr CAGR | 32.09 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹188 Cr | 62.02 | |
| Mar2025 | ₹116 Cr | -28.34 | |
| Mar2024 | ₹162 Cr | 62.66 | |
| Mar2023 | ₹99 Cr | 61.19 | |
| Mar2022 | ₹62 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 22.32 % |
| 5 Yr CAGR | 1.95 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 8.22 % | 22.32 | |
| Mar2025 | 6.72 % | -45.81 | |
| Mar2024 | 12.4 % | 25.89 | |
| Mar2023 | 9.85 % | 29.43 | |
| Mar2022 | 7.61 % | - | |
ASTRAZENECA PHARMA INDIA Earnings Per Share (EPS)
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | 62.01 % |
| 5 Yr CAGR | 32.09 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹75 | 62.01 | |
| Mar2025 | ₹46 | -28.33 | |
| Mar2024 | ₹65 | 62.64 | |
| Mar2023 | ₹40 | 61.20 | |
| Mar2022 | ₹25 | - | |
ASTRAZENECA PHARMA INDIA Return on Capital Employed (ROCE)
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | 46.74 % |
| 5 Yr CAGR | 15.82 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 31.24% | 46.74 | |
| Mar2025 | 21.29% | -37.27 | |
| Mar2024 | 33.94% | 38.59 | |
| Mar2023 | 24.49% | 41.07 | |
| Mar2022 | 17.36% | - | |
ASTRAZENECA PHARMA INDIA Share Price vs Sensex
| Current Share Price | : | ₹8,090.1 |
| Current MarketCap | : | ₹ 20,225.1 Cr |
| Updated EOD on | : | Jul 30,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ASTRAZENECA PHARMA INDIA | 3.9% |
-0.5% |
-10.4% |
| SENSEX | 2% |
1.9% |
-5.2% |
ASTRAZENECA PHARMA INDIA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 2.3% | 2.8% | 13.4% |
| BSE 1000 | 1.6% | 1.5% | 0% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 MULTICAP 50:25:25 | 1.5% | 1.4% | 0.8% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | 1.4% | 1.2% | 1.5% |
| NIFTY 500 EQUAL WEIGHT | 1.4% | 1.2% | 1.5% |
| NIFTY MIDSMALLCAP400 50:50 | 1.3% | 0.9% | NA |
| NIFTY SMALLCAP 500 | 0.9% | 0.2% | NA |
You may also like the below Video Courses
FAQ about ASTRAZENECA PHARMA INDIA Financials
How the annual revenues of ASTRAZENECA PHARMA INDIA have changed ?
The Revenues of ASTRAZENECA PHARMA INDIA have increased by 32.59% YoY .
How the Earnings per Share (EPS) of ASTRAZENECA PHARMA INDIA have changed?
The Earnings Per Share (EPS) of ASTRAZENECA PHARMA INDIA has increased by 62.01 % YoY .
Check out Intrinsic Value of Peers of ASTRAZENECA PHARMA INDIA
Compare Stock Analytics of Peers of ASTRAZENECA PHARMA INDIA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
